Spectrumceuticals ProbioFlora Multi Probiotic

Description

• Spectrumceuticals ProbioFlora Multi Probiotic is a comprehensive, 12-strain, micro-encapsulated, fridge-free probiotic formula offering a high-strength blend of clinically researched strains.
• Designed to provide up to 40 billion CFU per capsule, this multi-strain formula helps maintain healthy gut flora, especially during and after antibiotic use.
• Spectrumceuticals ProbioFlora Multi Probiotic supports optimal gastrointestinal system health, maintains the mucosal membrane, and supports a robust and healthy immune system function.
• Its stable, micro-encapsulated format ensures the survival of beneficial bacteria without the need for refrigeration, making it highly convenient for daily use and travel.
• Spectrumceuticals ProbioFlora Multi Probiotic contains Lactobacillus rhamnosus GG (ATCC 53103) and Bifidobacterium animalis subsp. lactis (DSM 15954), two extensively researched probiotic strains used in clinical probiotic formulations.

Indications

Gastrointestinal and flora support

• Helps support beneficial gut flora during antibiotic use
• Maintain/support intestinal health
• Maintain/support intestinal good/beneficial/friendly flora
• Maintain/support gastrointestinal system health
• Maintain/support gastrointestinal mucosal membrane health

General and immune support

• Maintain/support general health and wellbeing
• Maintain/support healthy immune system function
• Maintain/support immune system health
• Maintain/support healthy gastrointestinal immune function

Directions for use

Always read the label and follow the directions for use. Read the health warnings before purchase.

Warnings

No ARTG mandatory warnings

Active Ingredients

In total 40 billion CFU (colony forming units).

Excipient ingredients: microcrystalline cellulose, magnesium stearate, maltodextrin (maize/corn), colloidal anhydrous silica, purified water and size 0 hypromellose capsule.

Allergen Statement

No added yeast, gluten, wheat, dairy, preservatives or artificial colours and flavours. Suitable for vegans.

Storage

Store at room temperature, below 25 degrees Celsius, away from direct sunlight.

No need for refrigeration. Do not use if tamper evidence seal is missing, torn or broken.

FAQs

How do I store fridge free probiotics, are they stable?

For fridge-free, shelf-stable probiotics, please store in a cool dry place below 25°C, or refrigerate if you like. Prolonged excessive moisture and high heat will accelerate probiotic deterioration. High temperatures can kill probiotics, and exposure to temperatures above 46°C can increase the rate of loss rapidly, even for micro-encapsulated strains.

Why is the probiotic micro encapsulated?

Micro-encapsulation is a manufacturing process whereby the probiotic bacteria is coated with a thin plant based compound to protect the beneficial bacteria from heat and moisture degradation. The micro-encapsulation protects the probiotic and reduces the need for refrigeration.

What ingredients are used to create the micro encapsulation?

The micro-encapsulation contains the excipients, maltodextrin (tapioca starch), galactooligosaccharide, fructo-oligosaccharide, hypromellose, sodium alginate (agar), polysaccharide colloidal stabilizer (plant derived).

Spectrumceuticals ProbioFlora Multi Probiotic

Micro-encapsulation

Probiotic strains L. rhamnosus GG (ATCC 53103), L. paracasei ET-22, B. animalis subsp. lactis (DSM 15954), B. breve CCFM1025 and B. infantis YLGB-1496 are manufactured using a cryoprotective layer, a protective nutritional layer and an external barrier layer to reduce exposure to oxygen and moisture. In raw ingredient supplier comparative testing across five probiotic species, micro-encapsulated material was reported to have 16-25% higher gastric acid resistance and 28-34% higher bile-salt resistance than non-micro-encapsulated comparators.

L. rhamnosus LRa05, L. acidophilus LA85, L. plantarum Lp05, L. gasseri LG08, L. reuteri LR08, L. crispatus LCr86 and B. longum BL21 probiotic strains use a low-temperature electrostatic spray-drying process including resistant dextrin, peptone and related protective materials used to form an inner nutritional matrix, while colloids and electrostatic deposition form an external protective structure. The process is designed to support viable count, stress resistance, stability, flow and solubility.

Activ-Vial™ moisture protection

The 30-capsule and 60-capsule formulation use Activ-Vial™ screw-top packaging. The integrated 3-Phase Activ-Polymer™ sleeve surrounds the contents and adsorbs incoming moisture before it reaches the bottle headspace. The finished packs are induction sealed and tamper sleeved. This packaging supports storing at or below 25°C, so no refrigeration is required (can be refrigerated but do not freeze).

Clinical Studies

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients-A Systematic Review and Meta-Analysis. Antibiotics

Context: The rationale behind the administration of probiotics in gastrointestinal disorders is based on the hypothesis that they may assist in the normalisation of an unbalanced gastrointestinal flora. This is a systemic review and meta-analysis of 17 studies, including a pooled sample population of 3631 patients. The main outcomes were patient reported antibiotic associated diarrhoea (AAD).

Results: In the probiotic group the incidence of AAD was 8%, compared to 17.7% in the control group. This pooled result showed that the use of probiotics produced a statistically significant reduction in the incidence of AAD: RR 0.49; 95% CI 0.36 to 0.66.

A strain specific meta-analysis was also conducted on eight of the included studies, including those on L. rhamnosus GG. The result was similar to the overall pooled analysis and showed a beneficial effect of probiotics in the prevention of AAD. The subgroup analyses on L. rhamnosus GG and S, boulardii showed statistically significant lower risk of AAD, while this was not the case regarding the combination probiotic supplement of L. acidophilus La-5, and B. lactis Bb-12 (RR 0.79; 95% CI 0.47 to 1.33).

CONCLUSION: The high level of heterogeneity in the overall pooled results could no longer be detected in these three subgroups (I2=0%). A GRADE analysis indicated that the overall quality of evidence for this outcome was high. The pooled results were still statistically significant when the WHO definition of diarrhoea was applied.

Additional Studies

These studies are for education purposes only as they refer to chronic illnesses and therefore outside of allowed ARTG permitted indications for listed medicines within Australia. We do not make these claims within Australia. Spectrumceuticals probiotics are distributed throughout Asia and this information is for those practitioners. If you are seeing these studies within Australia it is because our server cannot geolocate your IP to identify which country you are accessing this tab from. This information is not for Australian practitioners nor the general public.

Alleviates Irritable Bowel Syndrome (laboratory and human clinical trial)

A B S T R A C T

Irritable bowel syndrome with diarrhea (IBS-D) is chronic intestinal dysfunction with diarrhea and other complicated clinical symptoms, and it has a great impact on the daily life and mental state of patients. Some studies have reported that ingestion of probiotics can significantly alleviate a variety of intestinal diseases. The purpose of this study was to investigate the IBS-D-alleviating effects of a probiotic strain, Lactobacillus plantarum (L. plantarum) CCFM8610, with multiple health-promoting effects. The study was a 12-week, randomized, double-blind, placebo-controlled, pilot clinical trial. Seventy-five patients were randomly assigned to receive the placebo, oligosaccharides, or L. plantarum CCFM8610 (1 × 1010 colony-forming units (CFU) per day), with a 2-week run-in period, an 8-week intervention period, and a 2-week follow-up observation period. The patients’ clinical symptoms and quality of life were examined by the IBS symptom severity scale (IBS-SSS) and the IBS quality of life scale (IBS-QOL). Changes in gut microbiota composition and diversity were measured at the end of the intervention period. The oral administration of L. plantarum CCFM8610 significantly decreased the IBS-SSS and IBS-QOL scores, reduced IBS-D symptom severity, recovered gut microbiota diversity, decreased the relative abundance of bloating-related genus Methanobrevibacter, and increased the relative abundance of butyric acid-producing genera, including Anaerostipes, Anaerotruncus, Bifidobacterium, Butyricimonas, and Odoribacter. These findings suggest that ingestion of L. plantarum CCFM8610 can significantly alleviate clinical symptoms and gut microbiota dysbiosis in IBS-D patients. The IBS-D-alleviating effect of L. plantarum CCFM8610 may be related to the increase in the relative abundance of butyric acid-producing genera in the intestine.

Multi-Probiotics ameliorate Major depressive disorder and accompanying gastrointestinal syndromes via serotonergic system regulation

A B S T R A C T

Major depressive disorder (MDD) is a leading global psychiatric disease. MDD is highly comorbid with gastrointestinal abnormalities, such as gut motility dysfunction. An effective strategy to manage depression and its accompanying gastrointestinal symptoms is warranted.

Objectives: Three probiotic strains (Bifidobacterium breve CCFM1025, Bifidobacterium longum CCFM687, and Pediococcus acidilactici CCFM6432) had previously been validated in mice to possess antidepressant-like potential. This study investigated the potential psychotropic effects of a combined three-strain probiotic intervention for human MDD patients. The mechanism of action was further investigated in the stress-induced depression mice model.

Methods: MDD patients were given a freeze-dried, mixed probiotic formula for four weeks. The patients’ psychometric and gastrointestinal conditions were evaluated using clinical rating scales before and after treatment. Their gut microbiome was also analysed using 16S rRNA gene amplicon sequencing. The mechanisms underlying the beneficial probiotic effects were determined using a chronic stress induced depressive mouse model.

Results: Multi-probiotics significantly reduced depression scores, and to a greater extent than the placebo (based on the Hamilton Depression Rating, Montgomery-Asberg Depression Rating, and Brief Psychiatric Rating Scales). Multi-probiotics also significantly improved the patients’ gastrointestinal functions (based on self-evaluation using the Gastrointestinal Symptom Rating Scale). Serotonergic system modification was demonstrated as the key mechanism behind the probiotics’ benefits for the brain and the gut.

Conclusion: Our findings suggest a novel and promising treatment to manage MDD and accompanying gut motility problems, and provide options for treating other gut-brain axis-related disorders.

Bifidobacterium longum mediated tryptophan metabolism to improve atopic dermatitis via the gut-skin axis

A B S T R A C T

Gut microbial disturbance affects allergic diseases including asthma, atopic dermatitis (AD) via the aberrant immune response. Some Bifidobacterial species and strains have been reported to improve AD via modulating immune-microbe interactions in patients. However, the effective metabolites and mechanism of alleviating AD in bifidobacteria remain to be elucidated. This study aimed to explore the microbial metabolite and mechanism of Bifidobacterium longum to improve AD. Based on shotgun metagenomic sequencing and UHPLC Q-Exactive-MS targeted metabolic experiments in vitro and in vivo, we focused on tryptophan metabolism and indole derivatives, which are endogenous ligands for aryl hydrocarbon receptor (AHR). Indole-3-carbaldehyde (I3C), a tryptophan metabolite of B. longum CCFM1029 activated AHR-mediated immune signaling pathway to improve AD symptoms in animal and clinical experiments. B. longum CCFM1029 upregulated tryptophan metabolism and increased I3C to suppress aberrant T helper 2 type immune responses, but these benefits were eliminated by AHR antagonist CH223191. Furthermore, B. longum CCFM1029 reshaped gut microbial composition in AD patients, increased fecal and serum I3C, and maintained the abundance of Lachnospiraceae related to tryptophan metabolism of gut microbiota. The results suggested that based on the interactions of the gut-skin axis, B. longum CCFM1029 upregulated tryptophan metabolism and produced I3C to activate AHR-mediated immune response, alleviating AD symptoms. Indole derivates, microbial metabolites of tryptophan, may be the potential metabolites of bifidobacteria to alleviate AD via the AHR signaling pathway.